Report

Collagen Solutions plc (COS.L) Update Year end trading update

The pre-year end trading update indicated a shortfall in sales of c.£0.36m for FY15,
which is expected to impact EBITDA by c.£0.26m; attributed to customer specific issues
which are not anticipated to impact the long term outlook for the Group. New client
wins, however, in the past quarter illustrate the industryÂ’s recognition of the
CompanyÂ’s product offering and technology. Moreover, the Company has yet to see
the benefits of upselling opportunities from the SLB acquisition.
Underlying
Collagen Solutions

Collagen Solutions is a holding company. Through its subsidiaries, Co. is engaged in the supply, development and manufacture of medical-grade collagen components and biomaterials for use in regenerative medicine, medical devices and in-vitro diagnostics. Co.'s primary products include medical-grade collagen, the primary protein in those tissues that provides a supportive environment for the cells, and processed native tissues such as pericardium, a tissue that surrounds the heart, and medical-grade collagen formulations. Co. supplies these as standard raw materials as well as in custom formulations that are used for the basic research to regenerative medicine therapies and medical devices.

Provider
Hardman & Co
Hardman & Co

We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.

Our expert team of sector analysts and market professionals collectively have over 400 years of experience.  This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.

Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.

Other Reports on these Companies
Other Reports from Hardman & Co

ResearchPool Subscriptions

Get the most out of your insights

Get in touch